L’OMS annonce un partenariat pour mettre en oeuvre une nouvelle technologie de “test sérologique” couillonaviral.
The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine. (source OMS)
The technology to date has resulted in four different tests, one of which has the potential to distinguish the immune response of COVID-19 infected individuals from vaccinated individuals.
En clair, cela détecte les vaccinés et les infectés… et donc de facto… les non vaccinés (rapidement et pas cher) !
La diffusion risque d’être massive, puisque :
The aim of the licence is to facilitate the rapid manufacture and commercialization of CSIC’s COVID-19 serological test worldwide. The agreement covers all related patents and the biological material necessary for manufacture of the test. CSIC will provide all know-how to MPP and/or to prospective licensees as well as training. The licence will be royalty-free for low- and middle-income countries and will remain valid until the date the last patent expires.
Cela arrive à point nommé… en plein délire omicronien et alors que les mesures coercitives pour imposer le dosage se multiplient dans le monde.
